Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion …
April 27, 2015 – Approximately 70 per cent of Lemtrada Patients Had Not Received Any Additional Lemtrada Treatment in the…
Drug prices to treat multiple sclerosis soar, point to larger problem
04.24.15 – OREGON STATE UNIVERSITY PORTLAND, Ore. – A new study released today found that drugs used to treat multiple sclerosis…
Stuart Schlossman
Researchers Report On What Happens When Multiple Sclerosis Patients Abandon Treatment
A team led by researchers at the New York University (NYU) Langone Medical Centerrecently assessed what happens when clinically stable patients…
Stuart Schlossman
Biogen to Focus on RRMS Disease Management, Treatment at Upcoming Conference
Biogen plans to present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 –…
Stuart Schlossman
FDA Approves Generic Multiple-Sclerosis Drug by Novartis’s Sandoz and Momenta
Momenta shares jump on approval of a version of Teva’s top-selling drug, Copaxone LISA BEILFUSS Updated April 16, 2015 4:21…
Stuart Schlossman
Teva files new FDA petition against generic Copaxone
Teva is battling against possible generic competition from September for the multiple sclerosis treatment. Teva Pharmaceutical Industries Ltd. has filed another…
Stuart Schlossman
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
SUNBEAM Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis Continues to Enroll According to Plan; Overall Phase 3 Program…
Stuart Schlossman
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)– Today Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency (EMA) has validated the companies’ Marketing…
Stuart Schlossman
New treatment for multiple sclerosis (LEMTRADA) slows disease progression, reduces relapses
SAN ANTONIO – A groundbreaking new treatment for multiple sclerosis is now available in the United States and is being used…
Stuart Schlossman
Guanabenz drug prevents myelin loss, alleviates symptoms of MS in animal models
March 13, 2015 An FDA-approved drug for high blood pressure, guanabenz, prevents myelin loss and alleviates clinical symptoms of multiple…
Stuart Schlossman
